Sysmex and bioMérieux form joint venture for Japanese diagnostics market
30 January 2008
Sysmex Corporation will take a 34% equity stake in
bioMérieux Japan Ltd, which will change its name to Sysmex bioMérieux Co
Ltd. The new company will promote and commercialize the entire bioMérieux
in-vitro diagnostics product range in Japan, starting in April.
French company bioMérieux has a presence in 150 countries through a
network of 36 subsidiaries. With sales of over
€1bn, it has a leading position in microbiology analysis with a
comprehensive offer of products for streamlined workflow and improved
quality in microbiology testing. bioMérieux has been operating in the
Japanese clinical diagnostics and industrial testing market up to now
through bioMérieux Japan, Ltd., a fully-owned subsidiary.
Corporation, based in Kobe, Japan, is a world leader in clinical laboratory
testing of blood, urine and other specimens, providing instruments and
reagents for clinical laboratory testing as well as laboratory information
systems. It had net sales of ¥101bn in
2007 (about US$1bn).
Microbiology testing is commonly practiced to
identify the causative bacteria and to measure their susceptibility to
certain antibiotics or drugs for the diagnosis and treatment of patients
suspected of having infectious diseases. The value of the microbiology
testing in Japan is estimated at approximately
¥30 billion per year and is regarded as a strategically important
market, the second largest worldwide.
Sysmex and bioMérieux have been developing their global partnership since
July 2007 when bioMérieux became a global partner to distribute Sysmex’s
highly standardized and automated UF-1000i, urine sediment analyzer to their
extensive clinical microbiology customer base. This new venture reinforces
the long-standing partnership between the two companies.
“We are extremely
pleased to engage in this joint venture with Sysmex for the Japanese
market,” declared Stéphane Bancel, Chief Executive Officer of bioMérieux.
“To date, bioMérieux Japan is number 19 in the Japanese IVD market, while
bioMérieux is number 7 worldwide. We have been lacking scale in several
critical functions like commercial operations and customer service. By
partnering with the number one diagnostics company in the Japanese market,
we will bring bioMérieux’s innovative products to a broader Japanese
customer base. We could not have found a better partner for this key
market,” he added.
"The collaboration with bioMérieux in the Japanese
market will allow us to leverage our well-reputed sales and service network
and infrastructure to provide expert solutions to customers," stated Hisashi
Ietsugu, President of Sysmex Corporation.